HR1109LRB099 21226 MST 46648 r

1
HOUSE RESOLUTION

 
2    WHEREAS, Fibromuscular dysplasia (FMD) is a disease that
3causes abnormal cell growth of the arterial wall; it can lead
4to areas of narrowing, beading, aneurysms, and dissections of
5the arterial wall; and
 
6    WHEREAS, Until recently, there has been very little
7progress in understanding the disease since it was first
8diagnosed in 1938; there is no known cause or cure for the
9disease and there are no set protocols to treat the disease;
10and
 
11    WHEREAS, FMD has always been considered and is still
12classified as a rare disease; many researchers now believe FMD
13is an under-diagnosed disease; some of the data suggest that
144-5% of the population may be affected by the disease; and
 
15    WHEREAS, Ninety percent of the patients affected by FMD are
16women, but men and children are also afflicted; there are
17different classifications of FMD; the two most common types are
18medial fibroplasia and intimal fibroplasia; unlike the adult
19population, children tend to be diagnosed with intimal
20fibroplasia, which can be more aggressive; some patients
21present with both types of the disease; there is no
22understanding of why there are differences; and
 

 

 

HR1109- 2 -LRB099 21226 MST 46648 r

1    WHEREAS, Individuals and families affected by
2fibromuscular dysplasia often experience problems such as a
3sense of isolation, difficulty in obtaining accurate and timely
4diagnosis, and optimal treatment options; and
 
5    WHEREAS, The Fibromuscular Dysplasia Society of America
6(FMDSA) was founded in March of 2003; over the past 13 years,
7this association has been active and successful with many
8programs, including public and physician awareness, patient
9support, and engaging with researchers from around the world;
10and
 
11    WHEREAS, The FMDSA is funding the United States Registry
12for Fibromuscular Dysplasia; previously it was thought that 75%
13of FMD cases affected the renal arteries, but recent data has
14proven that to be inaccurate; it is also very common to have a
155-year delay from onset of symptoms to diagnosis; and
 
16    WHEREAS, There is still much needed awareness and research
17of the disease; FMD patients present with many of the same
18complaints as other patients with more common conditions, such
19as hypertension, headaches, and dizziness; others present with
20TIA or stroke, dissection of an artery, aneurysm, swooshing
21noise in the ear, and renal infarction; children can present
22with basic symptoms such as high blood pressure, headaches,

 

 

HR1109- 3 -LRB099 21226 MST 46648 r

1insomnia, fatigue, and abdominal pain; misdiagnoses of FMD can
2lead to severe consequences and disability; and
 
3    WHEREAS, During the month of March each year, the FMDSA
4organizes a global observance of the issues associated with
5fibromuscular dysplasia; patients, medical professionals, and
6researchers join together to focus attention on fibromuscular
7dysplasia as a public health issue; therefore, be it
 
8    RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE
9NINETY-NINTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that we
10designate March of 2016 as "Fibromuscular Dysplasia Awareness
11Month" in the State of Illinois; and be it further
 
12    RESOLVED, That a suitable copy of this resolution be
13presented to the Fibromuscular Dysplasia Society of America as
14an expression of our esteem and respect.